BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.

The acquisition is centered around Biotheus’ main asset, BNT327/PM8002, which works by boosting the immune system to attack ...

BioNTech secured a leading candidate in the race one year ago by paying Biotheus $55 million upfront for the rights to PM8002 ...

With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

BioNTech SE (BNTX) announced Tuesday that it has signed an agreement to acquire Biotheus, a clinical-stage biotechnology company ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. The transaction is part ...

BioNTech, the German pharmaceutical company, announced on Wednesday that it has reached an agreement to acquire Biotheus, a Chinese biotechnology fir ...

In particular, the drug candidate BNT327/PM8002 developed by Biotheus will be a key area of focus after the deal closes. Last year, BioNTech obtained the exclusive global development and ...